Skip to main content
Premium Trial:

Request an Annual Quote

Sphere Fluidics Cyto-Mine Chroma

Sphere Fluidics has launched Cyto-Mine Chroma, the second generation of its flagship Cyto-Mine platform. The platform uses picodroplet technology to encapsulate single cells, assess cellular function, and isolate target cells for downstream expansion or analysis. The new system will still enable the functional screening of millions of cells per hour, but will feature a four-color laser and detector system, offering a greater degree of multiplexing compared to the first-generation platform, which featured one laser. The company will simultaneously launch its first multiplexed assay kit, improving the throughput and precision of clone selection by analyzing single cells for viability, productivity, and target specificity in one step, Sphere said. The platform will launch in the first quarter of 2025 and the company is currently taking orders, a spokesperson said.